Evidence map›Paper›PMID 24814516›Full record

ArticleOncogene2015

Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin.

N Moti, T Malcolm, R Hamoudi, S Mian, G Garland, C E Hook, G A A Burke, M A Wasik, O Merkel, L Kenner and 3 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 6 countries.

N MotiDivision of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK.
T MalcolmDivision of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK.
R HamoudiDivision of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK.
S MianMolecular Diagnostics and Personalised Therapeutics Unit, College of Applied Medical Sciences, University of Ha'il, Ha'il, Kingdom of Saudi Arabia.
G GarlandDivision of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK.
C E HookDepartment of Histopathology and Cytology, Addenbrooke's Hospital, Cambridge, UK.
G A A BurkeDepartment of Paediatric Oncology, Addenbrooke's Hospital, Cambridge, UK.
M A WasikDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
O Merkel1] Department for Translational Oncology, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany [2] European Research Initiative on ALK related malignancies (ERIA).
L Kenner1] European Research Initiative on ALK related malignancies (ERIA) [2] Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria [3] Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria.
E Laurenti1] Campbell Family Institute, Ontario Cancer Institute, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada [2] Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
J E Dick1] Campbell Family Institute, Ontario Cancer Institute, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada [2] Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
S D Turner1] Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK [2] European Research Initiative on ALK related malignancies (ERIA).
University of Cambridge · GBAddenbrooke's Hospital · GBGerman Cancer Research Center · DEMedical University of Vienna · ATUniversity Health Network · CAUniversity of Ha'il · SAUniversity of Pennsylvania · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells or tumour-propagating cells (TPCs) have been identified for a number of cancers, but data pertaining to their existence in lymphoma so far remain elusive. We show for the first time that a small subset of cells purified from human anaplastic lymphoma kinase (ALK)-positive and -negative, anaplastic large cell lymphoma cell lines and primary patient tumours using the side population (SP) technique have serial tumour-propagating capacity both in vitro and in vivo; they give rise to both themselves and the bulk tumour population as well as supporting growth of the latter through the production of soluble factors. In vivo serial dilution assays utilising a variety of model systems inclusive of human cell lines, primary human tumours and nucleophosmin (NPM)-ALK-induced murine tumours demonstrate the TPC frequency to vary from as many as 1/54 to 1/1336 tumour cells. In addition, the SP cells express higher levels of pluripotency-associated transcription factors and are enriched for a gene expression profile consistent with early thymic progenitors. Finally, our data show that the SP cells express higher levels of the NPM-ALK oncogene and are sensitive to an ALK inhibitor.

Indexed as

AdultAged, 80 and overAnaplastic Lymphoma KinaseAnimalsAntineoplastic Agents, PhytogenicApoptosisCell Line, TumorCell ProliferationCell SurvivalChildChild, PreschoolCrizotinibEtoposideFemaleGene Expression ProfilingHumansALK protein, humanAlk protein, mouseAnaplastic Lymphoma KinaseAntineoplastic Agents, PhytogenicCrizotinibEtoposideNPM1 protein, humanNuclear ProteinsNucleophosminProtein Kinase InhibitorsProto-Oncogene Proteins c-kitPyrazolesPyridinesReceptor Protein-Tyrosine Kinases

Identifiers

PMID24814516
OpenAlexW2081241850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.